Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia-Reference-Cited by-同舟云学术

Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia

Published:2007-12-12 Issue:1 Volume:51 Page:31-45
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pfefferkorn Jeffrey A.¹,Choi Chulho¹,Larsen Scott D.¹,Auerbach Bruce¹,Hutchings Richard¹,Park William¹,Askew Valerie¹,Dillon Lisa¹,Hanselman Jeffrey C.¹,Lin Zhiwu¹,Lu Gina H.¹,Robertson Andrew¹,Sekerke Catherine¹,Harris Melissa S.¹,Pavlovsky Alexander¹,Bainbridge Graeme¹,Caspers Nicole¹,Kowala Mark¹,Tait Bradley D.¹

Affiliation:

1. Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm070849r

Reference51 articles.

1. Primary prevention of coronary heart disease: role of cholesterol control in the United States

2. Serum Total Cholesterol and Long-term Coronary Heart Disease Mortality in Different Cultures

3. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.